These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 26990109)

  • 21. [Cost-effectiveness and safety of telaprevir and boceprevir for chronic hepatitis C in real-world clinical practice].
    Giménez-Manzorro Á; García-González X; Rodríguez-González CG; Ochoa-Palominos A; Sanjurjo-Sáez M; Clemente-Ricote G
    Gastroenterol Hepatol; 2015 Dec; 38(10):575-82. PubMed ID: 26321320
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of treatment-experienced hepatitis C patients with poor cost-effectiveness of pegylated interferon plus ribavirin from a real-world cohort.
    Liu TW; Tsai PC; Huang CI; Tsai YS; Wang SC; Ko YM; Lin CC; Chen KY; Liang PC; Lin YH; Hsieh MY; Hou NJ; Huang CF; Yeh ML; Lin ZY; Chen SC; Dai CY; Chuang WL; Huang JF; Yu ML
    J Formos Med Assoc; 2018 Jan; 117(1):54-62. PubMed ID: 28389143
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis.
    Asselah T; Bourgeois S; Pianko S; Zeuzem S; Sulkowski M; Foster GR; Han L; McNally J; Osinusi A; Brainard DM; Subramanian GM; Gane EJ; Feld JJ; Mangia A
    Liver Int; 2018 Mar; 38(3):443-450. PubMed ID: 28756625
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk of infections during interferon-based treatment in patients with chronic hepatitis C virus infection and advanced hepatic fibrosis.
    Maan R; van der Meer AJ; Hansen BE; Feld JJ; Wedemeyer H; Dufour JF; Lammert F; Manns MP; Zeuzem S; Janssen HL; de Knegt RJ; Veldt BJ
    J Gastroenterol Hepatol; 2015 Jun; 30(6):1057-64. PubMed ID: 25682797
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection.
    Younossi ZM; Park H; Saab S; Ahmed A; Dieterich D; Gordon SC
    Aliment Pharmacol Ther; 2015 Mar; 41(6):544-63. PubMed ID: 25619871
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study.
    Kieran JA; Norris S; O'Leary A; Walsh C; Merriman R; Houlihan D; McCormick PA; McKiernan S; Bergin C; Barry M
    BMC Infect Dis; 2015 Oct; 15():471. PubMed ID: 26503519
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of strategy-based approach to treatment of genotype 1 chronic hepatitis C.
    Zhao YJ; Khoo AL; Lin L; Teng M; Koh CJ; Lim SG; Lim BP; Dan YY
    J Gastroenterol Hepatol; 2016 Sep; 31(9):1628-37. PubMed ID: 26990023
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: Still a concern in clinical practice?
    Christensen S; Buggisch P; Mauss S; Böker KHW; Schott E; Klinker H; Zimmermann T; Weber B; Reimer J; Serfert Y; Wedemeyer H
    Addiction; 2018 May; 113(5):868-882. PubMed ID: 29359361
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Platelet Count Improvement after Chronic Hepatitis C Treatment among Cirrhotic Patients Who Achieved Sustained Virological Response: Realworld Results from 2186 Patients in Egypt.
    Badawi R; Soliman S; Aboali L; Elkadeem M; Elfert A; Elguindy AMA; Ullah MS; Abd-Elsalam S
    Endocr Metab Immune Disord Drug Targets; 2021; 21(7):1300-1305. PubMed ID: 32940191
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.
    Saab S; Hunt DR; Stone MA; McClune A; Tong MJ
    Liver Transpl; 2010 Jun; 16(6):748-59. PubMed ID: 20517909
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Medical resource utilisation and healthcare costs in patients with chronic hepatitis C viral infection and thrombocytopenia.
    Poordad F; Theodore D; Sullivan J; Grotzinger K
    J Med Econ; 2011; 14(2):194-206. PubMed ID: 21348807
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA experience.
    Dolmazashvili E; Abutidze A; Chkhartishvili N; Karchava M; Sharvadze L; Tsertsvadze T
    Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1223-1230. PubMed ID: 28857900
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-world outcomes of ledipasvir/sofosbuvir in treatment-naive patients with hepatitis C.
    Younossi ZM; Park H; Gordon SC; Ferguson JR; Ahmed A; Dieterich D; Saab S
    Am J Manag Care; 2016 May; 22(6 Spec No.):SP205-11. PubMed ID: 27266950
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and tolerability of an IFN-free regimen with DCV/ASV for elderly patients infected with HCV genotype 1B.
    Toyoda H; Kumada T; Tada T; Shimada N; Takaguchi K; Senoh T; Tsuji K; Tachi Y; Hiraoka A; Ishikawa T; Shima T; Okanoue T
    J Hepatol; 2017 Mar; 66(3):521-527. PubMed ID: 27890790
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents.
    Calvaruso V; Cabibbo G; Cacciola I; Petta S; Madonia S; Bellia A; Tinè F; Distefano M; Licata A; Giannitrapani L; Prestileo T; Mazzola G; Di Rosolini MA; Larocca L; Bertino G; Digiacomo A; Benanti F; Guarneri L; Averna A; Iacobello C; Magro A; Scalisi I; Cartabellotta F; Savalli F; Barbara M; Davì A; Russello M; Scifo G; Squadrito G; Cammà C; Raimondo G; Craxì A; Di Marco V;
    Gastroenterology; 2018 Aug; 155(2):411-421.e4. PubMed ID: 29655836
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A clinician's guide to the cost and health benefits of hepatitis C cure assessed from the individual patient perspective.
    McEwan P; Selvapatt N; Brown A; Thursz M; Bennett H; Webster S; Kalsekar A; Yuan Y; Brenner M; Gordon J
    Eur J Gastroenterol Hepatol; 2017 Feb; 29(2):208-214. PubMed ID: 27832039
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early Treatment in HCV: Is it a Cost-Utility Option from the Italian Perspective?
    Marcellusi A; Viti R; Damele F; Cammà C; Taliani G; Mennini FS
    Clin Drug Investig; 2016 Aug; 36(8):661-72. PubMed ID: 27234943
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis.
    Maan R; van Tilborg M; Deterding K; Ramji A; van der Meer AJ; Wong F; Fung S; Sherman M; Manns MP; Cornberg M; Hansen BE; Wedemeyer H; Janssen HL; de Knegt RJ; Feld JJ
    Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1821-1830.e6. PubMed ID: 27404965
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interference of hepatitis B virus dual infection in platelet count recovery in chronic hepatitis C patients with curative antiviral therapy.
    Huang CF; Yeh ML; Huang CI; Lin ZY; Chen SC; Dai CY; Huang JF; Chuang WL; Yu ML
    J Gastroenterol Hepatol; 2018 May; 33(5):1108-1114. PubMed ID: 29023927
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improvement of thrombocytopenia in hepatitis C-related advanced fibrosis patients after sustained virological response.
    Kee KM; Wang JH; Hung CH; Chen CH; Lee CM; Lu SN
    Dig Dis Sci; 2013 Feb; 58(2):556-61. PubMed ID: 23001404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.